Compare Stocks → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADPTNASDAQ:DNLINASDAQ:FATENASDAQ:VIRNASDAQ:XLRN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$3.21+11.1%$3.74$2.61▼$9.08$465.74M1.271.46 million shs1.99 million shsDNLIDenali Therapeutics$20.52-1.2%$18.60$15.45▼$33.31$2.86B1.341.19 million shs991,585 shsFATEFate Therapeutics$7.34$6.64$1.63▼$8.83$728.42M1.672.95 million shs2.72 million shsVIRVir Biotechnology$10.13+0.3%$10.18$7.72▼$27.48$1.37B0.421.10 million shs738,254 shsXLRNAcceleron Pharma$178.75$176.25$108.82▼$189.99$10.93B0.13572,759 shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+0.35%-14.50%-30.53%-45.78%-64.93%DNLIDenali Therapeutics+4.48%-2.44%+22.97%-5.38%-8.98%FATEFate Therapeutics+7.00%-1.21%+5.61%+86.29%+39.28%VIRVir Biotechnology+1.30%-0.69%-15.13%-1.85%-55.31%XLRNAcceleron Pharma0.00%0.00%0.00%0.00%0.00%Major Elon Musk Crypto Leak Revealed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies4.2126 of 5 stars3.32.00.04.23.12.50.6DNLIDenali Therapeutics4.402 of 5 stars3.53.00.04.73.32.50.0FATEFate Therapeutics3.6072 of 5 stars2.12.00.04.73.22.50.6VIRVir Biotechnology1.9553 of 5 stars3.31.00.00.01.13.31.3XLRNAcceleron PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies2.60Moderate Buy$7.25125.86% UpsideDNLIDenali Therapeutics3.00Buy$44.67117.67% UpsideFATEFate Therapeutics2.20Hold$6.73-8.35% DownsideVIRVir Biotechnology2.57Moderate Buy$34.38239.34% UpsideXLRNAcceleron PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest DNLI, ADPT, FATE, VIR, and XLRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024FATEFate TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$2.00 ➝ $6.003/19/2024FATEFate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.003/15/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.002/29/2024DNLIDenali TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $50.002/28/2024DNLIDenali TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$105.00 ➝ $95.002/28/2024DNLIDenali TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.002/27/2024FATEFate TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.002/27/2024FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $10.002/27/2024FATEFate TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$6.00 ➝ $7.002/27/2024FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $7.002/27/2024FATEFate TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$170.28M2.74N/AN/A$2.13 per share1.51DNLIDenali Therapeutics$330.53M8.64N/AN/A$7.42 per share2.77FATEFate Therapeutics$63.53M11.47N/AN/A$3.74 per share1.96VIRVir Biotechnology$39.49M34.63N/AN/A$11.82 per share0.86XLRNAcceleron Pharma$92.52M118.15N/AN/A$11.74 per share15.23Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$225.25M-$1.56N/AN/AN/A-132.29%-53.65%-27.24%5/1/2024 (Estimated)DNLIDenali Therapeutics-$145.22M-$1.08N/AN/AN/A-36.51%-13.50%-11.38%5/13/2024 (Estimated)FATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)VIRVir Biotechnology-$615.06M-$4.59N/AN/AN/A-713.69%-34.92%-27.73%5/2/2024 (Estimated)XLRNAcceleron Pharma-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/ALatest DNLI, ADPT, FATE, VIR, and XLRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2024Q4 2023DNLIDenali Therapeutics-$0.81-$0.86-$0.05-$0.86$3.38 millionN/A2/26/202412/31/2023FATEFate Therapeutics-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million 2/22/2024Q4 2023VIRVir Biotechnology-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million 2/14/2024Q4 2023ADPTAdaptive Biotechnologies-$0.32-$0.30+$0.02-$0.12$50.15 million$45.78 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AXLRNAcceleron PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A4.664.50DNLIDenali TherapeuticsN/A13.6513.65FATEFate TherapeuticsN/A8.488.48VIRVir BiotechnologyN/A9.059.05XLRNAcceleron PharmaN/A12.1412.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%DNLIDenali Therapeutics92.92%FATEFate Therapeutics97.54%VIRVir Biotechnology65.32%XLRNAcceleron Pharma90.35%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.20%DNLIDenali Therapeutics7.90%FATEFate Therapeutics5.04%VIRVir Biotechnology18.10%XLRNAcceleron Pharma1.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies709145.09 million137.55 millionOptionableDNLIDenali Therapeutics445139.16 million128.17 millionOptionableFATEFate Therapeutics18199.24 million94.24 millionOptionableVIRVir Biotechnology587135.03 million110.59 millionOptionableXLRNAcceleron Pharma31261.16 million60.12 millionOptionableDNLI, ADPT, FATE, VIR, and XLRN HeadlinesSourceHeadlineORBIMED CAPITAL GP II LLC's Net Worthbenzinga.com - February 27 at 3:47 PMXLRN Historical Datainvesting.com - October 20 at 10:08 AMMSD eyes March FDA decision on PAH drug sotaterceptpharmaphorum.com - October 16 at 12:20 AMBrexit Bargain Buys: 14 More Stocks Picked by Morgan Stanleythestreet.com - April 15 at 8:35 AMAstellas Pharma Increuters.com - March 17 at 6:17 AMHempStreet partners with MGC Pharma launches ArtemiChealth.economictimes.indiatimes.com - January 30 at 11:12 PMAcceleron Corp Becomes a Digital Correspondent Bankfinance.yahoo.com - December 14 at 8:40 AMPharma Contract Sales Market Report 2022-2032finance.yahoo.com - November 30 at 8:26 PMMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsreuters.com - November 21 at 12:55 PMPharmalittle: BIO CEO resigns amid board disagreements; Pfizer exec denies allegations over EU Covid-vaccine dealstatnews.com - October 11 at 10:48 AMBoost for Merck as Acceleron drug clears key phase 3 hurdlepharmaphorum.com - October 11 at 12:29 AMCentre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trialmsn.com - October 10 at 2:29 PMMerck touts positive results on key drug from $11.5 billion Acceleron mergerstatnews.com - October 10 at 8:14 AMLiquidia slumps as United, MannKind get FDA nod for rival therapyseekingalpha.com - May 23 at 4:11 PMMerck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyoutendpts.com - March 31 at 9:00 AM19 Charts to Calm Your Recession Fearsthestreet.com - January 20 at 10:48 PMXLRN May 2022 140.000 putfinance.yahoo.com - December 22 at 10:04 PMMerck Sells $8 Billion of Bonds to Fund Acceleron Acquisitionbloombergquint.com - December 7 at 7:55 PMMerck Completes Acquisition of Acceleron Pharmasmarteranalyst.com - November 23 at 9:33 AMMerck Closes Biggest Biotech Deal of the Yearfinance.yahoo.com - November 22 at 2:09 PMMerck announces completion of Acceleron Pharma acquisitionseekingalpha.com - November 22 at 7:52 AMMerck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN)nasdaq.com - November 21 at 8:45 AMMerck Completes Tender Offer to Acquire Acceleron Pharma Inc.us.acrofan.com - November 19 at 6:17 PMMarket cap of Acceleron Pharma Inc. [XLRN] reaches 10.99B – now what?dbtnews.com - November 18 at 10:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks AeroVironment Stock Rockets To New High: Price Could Double AgainMarch 6, 2024 10:22 AMView AeroVironment Stock Rockets To New High: Price Could Double AgainArm Holdings Stock Elevating on AI, Cloud, Automotive TailwindsMarch 26, 2024 9:05 AMView Arm Holdings Stock Elevating on AI, Cloud, Automotive Tailwinds2 Dollar Stores Taking Different Paths to ProfitabilityMarch 18, 2024 9:27 AMView 2 Dollar Stores Taking Different Paths to ProfitabilityAll Headlines Company DescriptionsAdaptive BiotechnologiesNASDAQ:ADPTAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Denali TherapeuticsNASDAQ:DNLIDenali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Fate TherapeuticsNASDAQ:FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Vir BiotechnologyNASDAQ:VIRVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Acceleron PharmaNASDAQ:XLRNAcceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.